Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome

被引:64
作者
Allampallam, K [1 ]
Shetty, V [1 ]
Mundle, S [1 ]
Dutt, D [1 ]
Kravitz, H [1 ]
Reddy, PL [1 ]
Alvi, S [1 ]
Galili, N [1 ]
Saberwal, GS [1 ]
Anthwal, S [1 ]
Shaikh, MW [1 ]
York, A [1 ]
Raza, A [1 ]
机构
[1] Rush Presbyterian St Lukes Med Ctr, Rush Canc Inst, Chicago, IL 60612 USA
关键词
myelodysplastic syndromes; cytokines; labeling index; apoptosis; tumor necrosis factor-alpha; transforming growth factor-beta; monocyte/macrophage cells;
D O I
10.1007/BF02982044
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Labeling index (LI), apoptosis, levels of 2 pro-apoptotic cytokines tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta), and the number of monocyte/macrophage cells that are the likely source of the cytokines were simultaneously measured in plastic-embedded bone marrow (BM) biopsy sections of 145 patients with myelodysplastic syndromes (MDS). TNF-alpha was correlated with TGF-beta (P =.001) and with monocyte/macrophage cells (P =.003). Patients with excess blasts in their marrows had a higher TGF-beta level (P =.01) and monocyte/macrophage number (P =.05). In a linear regression model, TGF-beta emerged as the most significant biological difference between patients who have excess of blasts and those who do not (P =.01). We conclude that in addition to TNF-alpha, TGF-beta also plays a significant role in the initiation and pathogenesis of MDS, and that a more precise definition of its role will likely identify better preventive and therapeutic strategies. (C) 2002 The Japanese Society of Hematology.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 37 条
  • [1] Allampallam K, 1999, ANTICANCER RES, V19, P5323
  • [2] ALVI S, 1996, P AM ASS CANC RES, V37
  • [3] BENNETT JM, 1982, BRIT J HAEMATOL, V51, P89
  • [4] Dar S, 1999, EUR J HAEMATOL, V62, P90
  • [5] A role for tumour necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome
    Gersuk, GR
    Beckham, C
    Loken, MR
    Kiener, P
    Anderson, JE
    Farrand, A
    Troutt, AB
    Ledbetter, JA
    Deeg, HJ
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) : 176 - 188
  • [6] International scoring system for evaluating prognosis in myelodysplastic syndromes
    Greenberg, P
    Cox, C
    LeBeau, MM
    Fenaux, P
    Morel, P
    Sanz, G
    Sanz, M
    Vallespi, T
    Hamblin, T
    Oscier, D
    Ohyashiki, K
    Toyama, K
    Aul, C
    Mufti, G
    Bennett, J
    [J]. BLOOD, 1997, 89 (06) : 2079 - 2088
  • [7] INCREASED SERUM INTERLEUKIN-6 LEVELS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    HEROLD, M
    SCHMALZL, F
    ZWIERZINA, H
    [J]. LEUKEMIA RESEARCH, 1992, 16 (6-7) : 585 - 588
  • [8] Blood flow to the haemopoietic bone marrow
    Iversen, PO
    [J]. ACTA PHYSIOLOGICA SCANDINAVICA, 1997, 159 (04): : 269 - 276
  • [9] Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia
    Kitagawa, M
    Yamaguchi, S
    Takahashi, M
    Tanizawa, T
    Hirokawa, K
    Kamiyama, R
    [J]. LEUKEMIA, 1998, 12 (04) : 486 - 492
  • [10] EXPRESSION AND GENOMIC CONFIGURATION OF GM-CSF, IL-3, M-CSF RECEPTOR (C-FMS), EARLY GROWTH-RESPONSE GENE-1 (EGR-1) AND M-CSF GENES IN PRIMARY MYELODYSPLASTIC SYNDROMES
    MARENI, C
    SESSAREGO, M
    MONTERA, M
    FUGAZZA, G
    ORIGONE, P
    DAMATO, E
    LERZA, R
    PISTOIA, V
    SCARRA, GB
    [J]. LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) : 135 - 141